Wirthumer-Hoche becomes Vice-Chair of EMA
Christa Wirthumer-Hoche, PhD, head of the Austrian Medicines and Medical Devices Agency, has been elected Vice-Chair of the European Medicines Agency (EMA) by the Management Board for a three-year period.
Christa Wirthumer-Hoche, PhD, head of the Austrian Medicines and Medical Devices Agency, has been elected Vice-Chair of the European Medicines Agency (EMA) by the Management Board for a three-year period. She succeeds Walter Schwerdtfeger, PhD, following his retirement as President of the German Federal Institute for Drugs and Medical Devices.
Wirthumer-Hoche was co-chair of the 2014 EuroMeeting of the Drug Information Association (DIA). According to DIA, she studied biochemistry and graduated from the Technical University, Vienna in 1981, and did her doctoral thesis at the Institute for Medical Physiology, graduating in 1983, after which she joined the Austrian National Institute for Quality Control of Drugs, focusing on the assessment of quality documentation. From 1998 to 2005, she was Head of the Licensing Division for medicinal products, in the Unit for Pharmaceutical Affairs in the Austrian Federal Ministry of Health and Women.
When the new Austrian Agency was founded in January 2006, she was Head of the Institute for Marketing Authorisation and Lifecycle Management of Medicinal Products, and was appointed Head of the Austrian Medicines and Medical Devices Agency on 1 October 2013.
Wirthumer-Hoche has also been involved in various European committees and working groups, including the Committee for Proprietary Medicinal Products (CPMP). In1999 she was appointed by the European Commission as Co-ordinator for the CTD Implementation in Europe (ICH-IWG). She is the Austrian Delegate in the Coordination Group for Mutual Recognition and Decentralised Procedures for human MPs (CMD-h) and chair of the Joint Working Group on ASMF-procedures.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
